RE:RE:RE:RE:RE:4 pm PR
Cash is king but unfortunately all the cash on hand is owed to holders of the convert with a shortfall of over 20 million !!
Nash clinical trial cost is over 100 million and Sort 1 platform in the tens of millions at a minimum.Add to that cash for working capital ...... The best case scenario was a partnering deal for Nash ,,, fantastic results in Phase 1 with a SP north of 10Usd combined to a substantial rise in revenues ftom legacy drugs....None of the above have yet materialized ...I am not throwing the towell as I dont see much downside from here but I see more and more limited options for the company to dig itself out of the hole....At the time of the options grants on Dec 1 I said that the only acceptable ethical reason to grant options in Dec rather than March /April was if a take over was in the cards ..... Of course not many here would be happy with a take over in the short term but in the end this could be the best solution for a company starving for cash
Wino115 wrote: If capital is raised prior to trial news and at a low price, we won't be the only disgusted shareholders. Soleus's two largest holdings have been crushed -- Bioatla is down form $40 to $12 and C3 is down from $50 to 30. They will not want to stump up more money and they will want to see this company maximize the share price, not crush it. They are now on our side of the equation.
The ideal scenario is 1a or 1b interim read gets share closer to $7 -$10. Do the ATM. Finish 1b and plan the various Phase 2's you are going for as registrational, and then get the full offering out with a solid list of good banks with Phase 2 info and hopefully at an even better level. If they do anything at these sub $5/$7 levels, it will be reflected in the board meeting probably.
houbahop wrote: From November 23, 2021 PR:
Theratechnologies Announces Renewal of Shelf Prospectus and Registration Statement; At-The-Market Facility to be Extended
"...provide for the potential offering in Canada and the United States of up to an aggregate of US $150,000,000 of common shares, preferred shares, subscription receipts, warrants, debt securities and units from time to time over a 25-month period after Canadian securities regulatory authorities have issued a receipt for the final short form base shelf prospectus. This shelf prospectus is intended to give the Company the flexibility to take advantage of financing opportunities when market conditions are favourable."...
https://stockhouse.com/news/press-releases/2021/11/23/theratechnologies-announces-renewal-of-shelf-prospectus-and-registration
******
I have a feeling the market is preparing itself for another deluge of shares and warrants.
I might be wrong but the $4.00 support level has been broken and there's not much in the way before $2.50